Provenance
Written by SPS and the College of Sexual and Reproductive Healthcare (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.
August 2025 – note the Faculty of Sexual and Reproductive Healthcare (FSRH) has now changed its name to the College of Sexual and Reproductive Healthcare (CoSRH). Some web pages and CoSRH documents will continue to display the FSRH name; where you see FSRH, this refers to CoSRH. All weblinks are still active.
PGD template attachment
The template PGD is attached below to download and use in conjunction with our implementation advice (SPS page).
More reproductive health PGD templates
- Etonogestrel (e.g. Nexplanon®) implant for contraception
- Ulipristal acetate 30mg tablets for emergency contraception
- Lidocaine injection for subdermal etonogestrel in contraception
- Lidocaine plus prilocaine cream for IUD insertion or removal
- Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception
- Levonorgestrel 1500 microgram tablets for emergency contraception
- Lidocaine 10mg/ml spray for IUD insertion or removal
- Copper Intrauterine Device (Cu-IUD)
- Combined hormonal contraceptive transdermal patch
- Combined hormonal contraceptive vaginal ring
- Combined oral hormonal contraceptive (COC) in reproductive health
- Medroxyprogesterone acetate (SC-DMPA) injection for contraception
- Medroxyprogesterone acetate (DMPA) IM injection for contraception
All PGD templates
National PGD, protocol and written instructions templates
National templates are developed with experts for clinical specialties. They reduce duplication and variation, and improve consistency of care.
Update history
- Planned review section removed as review now completed
- V2.3 PGD template removed as expired. Explanatory wording regarding versions of PGD template removed.
- Revised template due to minor clarifications following feedback.
- Planned update detail added
- Republished
- Version 3 published and explanatory wording added. Page reviewed
- Information added regarding name change of FSRH to CoSRH
- Version 2.3 published. Added statement to reflect new FSRH advice on desogestrel and risk of meningioma. Updated references.
- Details of a planned update to this template added
- Detail of planned update added following new FSRH advice
- Updated template published (changes detailed within document)
- Updated template published
- Title, URL and summary amended.
- Version 1 removed as expiring end March '23
- Version 2.0 PGD template added
- Published